SUSPECT ADVERSE REACTION REPORT

I. REACTION INFORMATION

1. PATIENT INITIALS (first, last)	1a. COUNTRY	2. DATE OF BIRTH			2a. AGE	3. SEX	3a. WEIGHT	4-6 REACTION ONSET			8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION
		Day	Month	Year				Day	Month	Year	
PRIVACY	GUATEMALA		PRIVACY		Unk	Male	Unk	21	AUG	2025	

7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data)
Event Verbatim [LOWER LEVEL TERM] (Related symptoms if any separated by commas)

Weakness in his arms and legs [Weakness of limbs]
Confusion in short periods [Confusion]

Case Description: This is a spontaneous report received from a Consumer or other non-HCP.

An adult male patient received lorlatinib (LORBRENA), since 12Aug2025.

(Continued on Additional Information Page)

- ☐ PATIENT DIED
- ☐ INVOLVED OR PROLONGED INPATIENT HOSPITALISATION
- ☐ INVOLVED PERSISTENT OR SIGNIFICANT DISABILITY OR INCAPACITY
- ☐ LIFE THREATENING

II. SUSPECT DRUG(S) INFORMATION

14. SUSPECT DRUG(S) (include generic name)
#1) Lorbrena (LORLATINIB) Film-coated tablet

15. DAILY DOSE(S)
#1) UNK

16. ROUTE(S) OF ADMINISTRATION
#1) Unknown

17. INDICATION(S) FOR USE
#1) Unknown

18. THERAPY DATES(from/to)
#1) 12-AUG-2025 / Unknown

19. THERAPY DURATION
#1) Unknown

20. DID REACTION ABATE AFTER STOPPING DRUG?
☐ YES ☐ NO ☐ NA

21. DID REACTION REAPPEAR AFTER REINTRODUCTION?
☐ YES ☐ NO ☐ NA

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)

23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)

From/To Dates	Type of History / Notes	Description
Unknown		

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER
Pfizer S.A.
Laura Arce Mora
Avenida Escazú, Torre Lexus, piso 7. Escazú
San jose, COSTA RICA

26. REMARKS

24b. MFR CONTROL NO.
202500169690

24c. DATE RECEIVED BY MANUFACTURER
21-AUG-2025

24d. REPORT SOURCE
☐ STUDY ☐ LITERATURE
☐ HEALTH PROFESSIONAL ☒ OTHER: Spontaneous

DATE OF THIS REPORT
27-AUG-2025

25a. REPORT TYPE
☒ INITIAL ☐ FOLLOWUP:

25b. NAME AND ADDRESS OF REPORTER
NAME AND ADDRESS WITHHELD.

ADDITIONAL INFORMATION

7+13. DESCRIBE REACTION(S) continued

The patient's relevant medical history and concomitant medications were not reported.
The following information was reported: CONFUSIONAL STATE (non-serious) with onset 21Aug2025, outcome "unknown", described as "Confusion in short periods"; MUSCULAR WEAKNESS (non-serious) with onset 21Aug2025, outcome "unknown", described as "Weakness in his arms and legs". The action taken for lorlatinib was unknown.

Additional information: The patient reported that he had weakness in his arms and legs. In addition, he presented confusion in short periods.